Oxford GlycoSciences, the UK biotech company, and its adviser, Goldman Sachs, have begun hunting for buyers for the business after withdrawing a recommendation for an £83m (€122m) merger with Cambridge Antibody Technology (CAT).

The company withdrew its recommendation because a fall in CAT's share price meant it was worth 18% less than a rival offer from Celltech, another UK biotech group.